Alligator Bioscience AB is a pharmaceutical company based in Lund that specializes in the development of antibody-based drugs aimed at treating cancer. The company focuses on tumor-directed immunotherapy, which is designed to enhance the body’s immune response against cancer cells. This innovative approach is part of a broader commitment to advancing cancer therapies through research and development.
In addition to its core activities in drug development, Alligator Bioscience engages in various research and development events and emphasizes collaboration and partnerships within the biotechnology sector. The company also publishes financial calendars and reports, providing transparency regarding its operations and financial health. Furthermore, it conducts webinars related to interim reports, allowing stakeholders to stay informed about its progress and developments. Alligator is also involved in rights issues and subscription undertakings, reflecting its active participation in the financial aspects of biotechnology advancement.